(CercleFinance.com) – Bristol Myers Squibb today announced the presentation of data from more than 55 studies across its oncology portfolio in more than 10 tumors at the 2023 European Society of Medical Oncology Congress ( ESMO) which will be held from October 20 to 24 in Madrid, Spain.
The data to be presented support the role of Opdivo and Opdivo-based combinations in early and metastatic stages of several cancer types, particularly in patient groups with high unmet need.
Additional data will highlight the potential of repotrectinib in patients with TKI-naïve and pretreated NTRK-positive solid tumors, including non-small cell lung cancer (NSCLC), as well as the benefit of treatment with Opdualag, fixed-dose double immunotherapy.
‘We look forward to sharing research conducted during this year’s ESMO Congress on our immunotherapies and targeted therapies in metastatic disease and early stages of several tumor types, including bladder cancer, melanoma and cancer. of the lung,’ said Samit Hirawat, MD, executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb.
“This new data highlights our leading development program for Opdivo and Opdivo-based combinations in early stages of cancer.”
Copyright (c) 2023 CercleFinance.com. All rights reserved.